What We're Reading: Page 136
Industry reads hand-picked by our editors
Oct 15, 2021
-
The Washington Post
Biden zeroes in on Califf to head FDA as deadline nears
-
Forbes
The Inside Story Of How SoftBank-Backed Zymergen Imploded Four Months After Its $3 Billion IPO
-
The Wall Street Journal
Johnson & Johnson Places Talc Injury Claims in Bankruptcy
-
Axios
Democrats' attempt to lower private market prescription drug prices is likely to fail
Oct 14, 2021
-
Nature
‘I hope you die’: how the COVID pandemic unleashed attacks on scientists
-
STAT
Pfizer uses warranties to refund costs when cancer drug fails
-
Boston Business Journal
Scientist behind Vertex CF drugs launches new startup with Atlas
-
In The Pipeline
Molnupiravir Mutations
Oct 13, 2021
-
The Financial Times
Covid success of mRNA vaccines opens way to a new generation of drugs
-
Bloomberg
Bristol-Myers Is Said to Have Weighed Offer for Acceleron
-
Reuters
Lonza shores up investment budget to capitalise on biotech boom
-
Endpoints News
As TRIPS council meets, the IP waiver for vaccines is on life support ahead of a December deadline
Oct 12, 2021
-
The Wall Street Journal
Johnson & Johnson’s Top Scientist to Depart
-
Chemical & Engineering News
Preventive cancer vaccine based on neoantigens gets put to the test
-
Evaluate Vantage
Triple meeting – low-profile assets boost Merus and Bicycle
-
The Financial Times
Covid response hampered by population data glitches
Oct 11, 2021
Oct 08, 2021
Oct 07, 2021
-
The New York Times
First Malaria Vaccine Approved by W.H.O.
-
STAT
Amgen's Lumakras disappoints in combination with other drugs
-
Roll Call
FDA’s internal turmoil could impact boosters, shots for kids
-
MIT Technology Review
Tech millionaire Steve Kirsch went from covid trial funder to misinformation superspreader
Previous
